Details of the Drug Reposition

General Information of This Drug (ID: DMAHOVJ)

Drug Name
Crizanlizumab   DMAHOVJ
Synonyms SEG101
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Vaso-occlusive crisis DISL7897 BE2Y Approved [1]
------------------------------------------------------------------------------------
1 Phase 4 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Sickle-cell disorder DISW25G5 3A51 Phase 4 [2]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 ClinicalTrials.gov (NCT04662931) An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients. U.S. National Institutes of Health.